Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Ischemic Stroke ll: Pathophysiology

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Hemorrhagic Stroke ll: Pathophysiology

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EUCARDIA: A web-based platform for the CVD prediction using ML techniques in the Greek population.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese·2026

Same author

"The emerging role of lymphocytes in post-stroke inflammation: A treatable target and review of current pharmacological evidence in humans".

Brain, behavior, & immunity - health·2026

Same author

Particular Water Organization in Homogeneous Water Mixtures of Amphiphilic Polystyrene-<i>block</i>-poly(methoxydiethylene glycol acrylate) Diblock Copolymer with Thermoresponsive Behavior.

The journal of physical chemistry. B·2025

Same author

Association of patient characteristics with clinical outcomes in a cohort of hospitalised patients with SARS-CoV-2 infection in a Greek referral centre for COVID-19.

Epidemiology and infection·2023

Same author

Association of patient characteristics with clinical outcomes in a cohort of hospitalised patients with SARS-CoV-2 infection in a Greek referral centre for COVID-19 - Corrigendum.

Epidemiology and infection·2023

Same author

Is nuchal translucency measurement feasible in early pregnancy?

Hippokratia·2023

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Paraoxonase gene polymorphisms and stroke severity.

L Lazaros¹, S Markoula, A Kyritsis

¹Laboratory of Medical Genetics, Universit of Ioannina, Ioannina, Greece.

European Journal of Neurology

|November 26, 2009

Summary

This summary is machine-generated.

The PON2 311C allele may predispose individuals to severe ischemic stroke. Further research is needed to confirm the link between paraoxonase gene polymorphisms and stroke severity.

More Related Videos

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

Related Experiment Videos

Last Updated: Jun 18, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

Area of Science:

Genetics
Neurology
Cardiovascular Disease

Background:

Paraoxonase (PON) is an HDL-associated enzyme crucial in preventing low-density lipoprotein oxidation and atherosclerosis.
Genetic variations in PON genes, specifically polymorphisms, can influence enzyme activity.
Atherosclerosis and its complications, like ischemic stroke, are significant health concerns.

Purpose of the Study:

To investigate the association between polymorphisms in the three Paraoxonase (PON) genes and ischemic stroke.
To determine if specific PON gene variants are linked to an increased risk or severity of ischemic stroke.

Main Methods:

A case-control study involving 178 ischemic stroke patients and 181 healthy controls.
Analysis of polymorphisms in PON1 (Q/R 192 and M/L 55) and PON2 (S/C 311).
Severity of ischemic stroke assessed using the Modified Rankin Scale.

Main Results:

A significant increase in the PON2 311C allele was observed in patients with severe ischemic stroke (P = 0.02, OR = 2.215).
No significant differences in genotype or allele distribution were found between the overall patient group and healthy controls.
The PON2 311C allele showed a correlation with stroke severity, not overall susceptibility.

Conclusions:

The PON2 311C allele is suggested as a potential predisposing factor for severe ischemic stroke.
Further large-scale, multicenter prospective studies are recommended to validate these findings.
Understanding PON polymorphisms' role could aid in predicting stroke severity and developing targeted interventions.